Everything below concerns REV-ERB agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-14. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Calcium ions are one type of second messengers and are responsible for many important physiological functions including muscle contraction, fertilization, and neurotransmitter release. The ions are normally bound or stored in intracellular components (such as the endoplasmic reticulum(ER)) and can be released during signal transduction. The enzyme phospholipase C produces diacylglycerol and inositol trisphosphate, which increases calcium ion permeability into the membrane. Active G-protein open up calcium channels to let calcium ions enter the plasma membrane. The other product of phospholipase C, diacylglycerol, activates protein kinase C, which assists in the activation of cAMP (another second messenger).
=== Exhibition in June 1933 in Paris === General Gouraud granted his patronage for an exhibition in the function hall of the town hall of the 13th district of Paris. The exhibition, Visions féeriques d’Orient (Fantasy Perspectives of the East), grouped together some 172 plates: 80 plates from the Basilique de Sainte-Sophie de Constantinople (Basilica of Hagia Sophia of Constantinople) and 92 plates from L'Art Islamique en Orient (Islamic Art in the East). Raymond’s name was not mentioned on the cover of the exhibition brochure.
=== Genome === B. canis has two distinct circular chromosomes, a structure conserved across the Brucella genus. For the reference strain ATCC 23365, Chromosome 1 has 2,199 genes, and Chromosome 2 has 1,224 genes. These two circular chromosomes contain multiple distinct shared regions, which can be attributed to horizontal gene transfer. Evidence suggests that Chromosome 2 was derived from a plasmid, though both chromosomes contain essential genes. B. canis and B. suis in particular share extremely similar genomic content, exceeding what would traditionally be expected from similarities between different species in the same genus. Genomic analysis suggests that B. canis is part of the B. suis clade, and represents a host-adapted variant of B. suis. Despite this significant similarity, it is still possible to differentiate between B. canis and B. suis using PCR assays targeting specific known genetic variations. The most notable distinguishing factor is the lack of O-polysaccharide in its lipopolysaccharide, causing the naturally "rough" phenotype for B. canis in contrast to B. suis which retains the naturally "smooth" phenotype.
Sources: en.wikipedia.org
In September 2020, the US Food and Drug Administration (FDA) required the boxed warning for all benzodiazepine medicines to be updated to describe the risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions consistently across all the medicines in the class.
The National Cancer Institute provides additional information on the health effects from exposure to 131I in fallout, as well as individualized estimates, for those born before 1971, for each of the 3070 counties in the US. The calculations are taken from data collected regarding fallout from the nuclear weapons tests conducted at the Nevada Test Site. On 27 March 2011, the Massachusetts Department of Public Health reported that 131I was detected in very low concentrations in rainwater from samples collected in Massachusetts, and that this likely originated from the Fukushima power plant. Farmers near the plant dumped raw milk, while testing in the United States found 0.8 pico-curies per liter of iodine-131 in a milk sample, but the radiation levels were 5,000 times lower than the FDA's "defined intervention level". The levels were expected to drop relatively quickly
== New York Giants == The New York Giants Fearsome Foursome consisting of ends Andy Robustelli and Jim Katcavage, and tackles Rosey Grier and Dick Modzelewski, first played together on the Giants 1956 NFL Championship Team. They were considered pioneers in inaugurating a defensive era in professional football. The Giants' Fearsome Foursome broke up as a group before the start of the 1963 season, when the Giants traded Grier to the Los Angeles Rams for John LoVetere. Other than during Grier's Army service in 1957, and a period of injury for Katcavage at the end of the 1960 season, the four played together in every minute of every game from 1956 to 1962. Robustelli is in the Pro Football Hall of Fame. In addition to winning the championship in 1956, the Giants went to four other NFL championship games, losing to the Baltimore Colts in 1958 (known as "the Greatest Game Ever Played"), and 1959 and the Green Bay Packers in 1961 and 1962. They were "largely responsible" for the Giants' success during these years. In the 1957 season the New York Daily News, a major New York city tabloid, ran an article and sketches of the New York Giants' line consisting of ends Andy Robustelli and Jim Katcavage, and tackles Rosey Grier and Dick Modzelewski and a headline that read "A Fearsome Foursome." They were known as the Fearsome Foursome by at least 1959, supported by an actual photograph of the four.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.